ReviewNature reviews. Microbiology2025
Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics.
Review in Nature reviews. Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence of fluoroquinolone resistance inFrontiers in cellular and infection microbiology · 2026Pooled it
- Development of a PapG-AcmA surface-associated antigen on Lactobacillus reuteri as a vaccine strategy against uropathogenic Escherichia coli.Archives of microbiology · 2026Article
- Effect of human urinary microenvironment and fluid flow on antibiotic and phage therapy efficacy against uropathogenic Escherichia coli.Nature communications · 2026Article
- Genomic and phenotypic characterization of Klebsiella pneumoniae phage KP Ø1: a novel lytic Slopekvirus targeting uropathogenic multidrug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Targeting the human gut microbiome: a comparative review of probiotics, prebiotics, synbiotics, and postbiotics.Journal of advanced research · 2026Review
- Integrated phenotypic-genotypic characterization of antimicrobial resistance in uropathogens: implications for targeted therapy in a North Indian cohort.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Synergy Between a Silver-Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage.Molecular microbiology · 2026Article
- Efficacy of Probiotic Supplementation for Preventing Pediatric Urinary Tract Infections: A GRADE-Based Dose-Response Meta-Analysis.Health science reports · 2026Review
- Urinary tract infections in children.Nature reviews. Urology · 2026Review
- Combating multidrug-resistant pathogens, breast cancer (MCF-7) and hepatocellular carcinoma (HepG2) using biofabricated zinc oxide nanoparticles.Scientific reports · 2026Article
- Rapid screening of urinary tract infections: quantitative flow cytometry versus dipstick testing in a hospital cohort.Infection · 2026Article
- Function-specific epistasis shapes evolutionary trajectories towards antibiotic resistance.Nature communications · 2026Article
- Update to the management of recurrent urinary tract infections in women aged 16 years and older.Drug and therapeutics bulletin · 2026Review
- Significant variability in virulence factors and antibiotic resistance of uropathogenic Escherichia coli strains may be counteracted by their susceptibility to lytic bacteriophages.Scientific reports · 2026Article
- Rapid diagnostics innovations for urinary tract infections using molecular biology, artificial intelligence and antimicrobial resistance surveillance: a comprehensive review.Molecular biology reports · 2026Review
- Bacterial profile, antimicrobial susceptibility, and associated factors of urinary tract infection among people living with HIV at Debre Markos Comprehensive Specialized Hospital, Ethiopia.Scientific reports · 2026Article
- PVC microplastics facilitate uropathogenic Escherichia coli pathogenicity by enhancing host cell invasion and mitochondrial-dependent pyroptosis.Nature communications · 2026Article
- Genomic diversity and high-risk lineages in clinical Escherichia coli from Mexico.Archives of microbiology · 2026Article
- Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection.JAC-antimicrobial resistance · 2026Article
- Mechanisms Linking Recurrent Bacterial Urinary Tract Infections to Chronic Kidney Disease Progression.International journal of molecular sciences · 2026Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Urinary tract infections (UTIs), which include any infection of the urethra, bladder or kidneys, account for an estimated 400 million infections and billions of dollars in health-care spending per year. The most common bacterium implicated in UTI is uropathogenic Escherichia coli, but diverse pathogens including Klebsiella, Enterococcus, Pseudomonas, Staphylococcus and even yeast such as Candida species can also cause UTIs. UTIs occur in both women and men and in both healthy and immunocompromised patients. However, certain patient factors predispose to disease: for example, female sex, history of prior UTI, or the presence of a urinary catheter or other urinary tract abnormality. The current clinical paradigm for the treatment of UTIs involves the use of antibiotics. Unfortunately, the efficacy of this approach is dwindling as the prevalence of antimicrobial resistance rises among UTI isolates, and the immense quantity of antibiotics prescribed annually for these infections contributes to the emergence of resistant pathogens. Therefore, there is an urgent need for new antibiotics and non-antibiotic treatment and prevention strategies. In this Review, we discuss how recent studies of bacterial pathogenesis, recurrence, persistence, host-pathogen interactions and host susceptibility factors have elucidated new and promising targets for the treatment and prevention of UTIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.